Nature子刊：赵蔚团队发现，靶向相分离，治疗胶质母细胞瘤

Core Insights - Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with a median survival of only 12-18 months post-diagnosis, and current treatments have limited efficacy in extending life expectancy [2][3] - A recent study published by Zhao Wei's team in Nature Cell Biology identifies HOXB3 condensation in the core regulatory circuitry (CRC) of GBM as a potential therapeutic target, suggesting that targeting HOXB3 with the peptide P621-R9 can selectively reduce tumorigenic potential in patient-derived xenograft models [2][5] Research Findings - The study utilized single-cell CUT&Tag analysis to investigate H3K27ac modifications, revealing significant heterogeneity within the GBM core regulatory circuitry [5] - The research highlighted the heterogeneous condensation state of HOXB3, influenced by its intrinsic disordered region (IDR) and interaction with RUNX1, which drives phenotypic expression [5] - The synthesized peptide P621-R9 effectively disrupts HOXB3 condensation, alters chromatin structure, and reduces transcription at super-enhancer-associated oncogenic loci in GBM cells exhibiting HOXB3 condensation [5][6] Implications for Treatment - These findings underscore the critical role of condensation in the heterogeneity of GBM and suggest that peptide-based targeted therapies for different GBM subgroups may represent a promising new direction for treatment [6] - A concurrent article in Nature Cell Biology discusses the potential origins of GBM heterogeneity from the activation of various gene core regulatory circuits, emphasizing HOXB3's central role in GBM CRC and the therapeutic potential of peptide-mediated targeting [6]